Project Details
Description
A PHASE 2 STUDY OF ALISERTIB IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH HR+, HER2-NEGATIVE RECURRENT OR METASTATIC BREAST CANCER
| Status | Active |
|---|---|
| Effective start/end date | 9/25/24 → 9/24/35 |
Funding
- PUMA BIOTECHNOLOGY INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.